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Premenopausal femalesAbstract Introduction: Osteoporosis is a main extra-articular complication of rheumatoid arthri-
tis (RA) which may lead to fractures. Interleukin-17 (IL-17) is one of the cytokines which plays a
signiﬁcant role in RA pathogenesis and promotion of osteoporosis.
Aim of the work: To study the relation between serum IL-17 levels and the risk of osteoporotic
fractures in pre-menopausal RA patients.
Patients and methods: Twenty-ﬁve premenopausal RA patients and 20 matched healthy controls
were included in this study. All patients were subjected to detailed history taking, thorough clinical
examination, disease activity assessment using the disease activity score-28 (DAS-28) and disability
was assessed using Health Assessment Questionnaire–Disability Index (HAQ-DI). Bone mineral
density and serum IL-17 levels were measured in patients and the control. Fracture Risk
Assessment Tool (FRAX index) was also calculated.
Results: The mean age of RA patients was 38.8 ± 7.6 years. The BMD was signiﬁcantly reduced
in patients compared to the control at the femur neck (p= 0.008), wrist (p= 0.046) and at the lum-
bar spine (p= 0.005). The Z score was below the expected range for age in 36% compared to 5% in
the control (p= 0.03). Serum IL-17 concentrations were signiﬁcantly higher in patients
(5.99 ± 1.22 pg/ml) compared to the control (3.73 ± 2.15 pg/ml) (p< 0.001). Serum IL-17 levels
showed a signiﬁcant correlation with FRAX scores. Z-score interpretation showed a strong positive
86 H.K. Korayem et al.signiﬁcant correlation with FRAX index; major osteoporotic fractures and hip fracture (p= 0.005
and p= 0.013, respectively) in patients.
Conclusion: The premenopausal Rheumatoid arthritis patients showed a high fracture probabil-
ity. Interleukin-17 serum level is associated with higher liability to fractures among rheumatoid
patients.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid Arthritis (RA) is the most common form of
inﬂammatory arthritis in adults and is characterized by
chronic, progressive, systemic inﬂammation leading to sub-
stantial pain, disability, and other comorbidities [1]. It affects
0.5–1% of the adult population worldwide. Like in other
autoimmune diseases females are affected more often than
males [1].
Osteoporosis (OP) is recognized as the main extra-articular
complication of RA and is classiﬁed into periarticular and gen-
eralized types. The risk factors for the development of OP in
rheumatoid patients include the traditional OP risk factors
on one side which constitute older age, female sex, menopause,
lower body mass index (BMI), cigarette smoking and alcohol
consumption [2,3]. On the other side the RA disease associated
OP risk factors include the inﬂammatory process, disease
activity, RA disease duration, decreased physical activity and
glucocorticoid usage [1,4–6].
Osteoporotic fractures (OFs) are fractures associated with
low bone mineral density (BMD) and include spine, forearm,
hip and shoulder fractures. Osteoporotic fractures can cause
substantial pain and severe disability, often leading to a
reduced quality of life, and hip and vertebral fractures are
associated with decreased life expectancy [7]. Fracture Risk
Assessment Tool (FRAX index) is a computer-based algo-
rithm developed by the WHO Collaborating Centre for meta-
bolic bone diseases. The outputs of FRAX are the 10-year
probability of major osteoporotic fractures (hip, spine,
humerus or wrist fracture) and the 10-year probability of hip
fracture [8].
Osteoporosis in RA is mediated by many cytokines such as
interleukin-6 (IL-6), IL-1, tumor necrosis factor-a (TNF-a)
and IL-17 [9]. Interleukin-17 contributes to cartilage and bone
destruction by acting as a potent inductor of the expression of
matrix metalloproteinases (MMPs) and receptor activator of
nuclear factor (NF)-jb ligand (RANKL) in rheumatoid syn-
oviocytes and osteoblasts, being an important promoter of
osteoclastogenesis [10].
IL-17 is a pro-inﬂammatory cytokine that is secreted as a
dimer by T helper 17 (TH17) cells. It is already demonstrated
that in human RA, IL-17 plays a key role in the synergistic or
additive effects expressed together with TNF-a and IL-1 [11].
The direct proinﬂammatory effects of IL-17 may be small
when compared to those of IL-1 and TNF-a. However, IL-
17 enhances many of the effects of IL-1 and TNF-a and stim-
ulates their production from human macrophages. IL-17 also
enhances IL-1-mediated IL-6 production by RA synovial tis-
sue ﬁbroblasts, as well as TNF-a induced synthesis of IL-1,
IL-6 and IL-8. In short, a major role of IL-17 may beamplifying the effects of macrophage derived proinﬂammatory
cytokines and hence be the missing link between T cells in the
RA joint and the effector phase of RA [12].
The aim of the current study was to study the relation
between serum IL-17 levels and risk of osteoporotic
fractures (hip, vertebral and wrist) in pre-menopausal RA
patients.2. Patients and methods
The present case control study included 25 premenopausal
females with RA that constitute patients group. They fulﬁlled
the 2010 American College of Rheumatology/European
League Against Rheumatism (ACR/EULAR) classiﬁcation
criteria for RA [13]. They were collected from the outpatient
clinic of the Physical Medicine, Rheumatology and
Rehabilitation Department, Faculty of Medicine, University
of Alexandria. We excluded patients with a history or current
use of any medications for management of OP (except for cal-
cium and/or vitamin D) including bisphosphonates, hormone
replacement therapy or raloxifene. Patients with other systemic
or local bone disease that lead to OP were excluded. Twenty
healthy premenopausal women matching the age of the
patients were selected to constitute the control group. Both
groups gave their informed consent to participate in the study.
The study was approved by the institutional ethics committee.
All the enrolled patients were subjected to a detailed history
taking, thorough clinical examination, disease activity assess-
ment using the disease activity score 28 (DAS-28) [14] and
the disability was assessed by using Health Assessment Quest
ionnaire–Disability Index (HAQ-DI) [15].
The Bone Mineral Density (BMD) measurements were
done by dual-energy X-ray absorptiometry (DEXA) for all
subjects by a Lunar Prodigy Advanced DEXA scanner system.
As all the studied females in this study were premenopausal
and according to The International Society for Clinical
Densitometry (ISCD) recommendation, instead of T-scores,
ethnic or race adjusted Z-scores were used. Z-score was calcu-
lated as a relationship between 2 norms by comparing the
patient’s BMD to the expected BMD for the patient’s age
and sex. The difference between the patient’s score and the
norm is expressed in SD above or below the mean.
Fracture assessment was done using the FRAX index for
patients and controls. The outputs of FRAX index are the
10-year probability of a major osteoporotic fracture (hip, spine
or wrist fracture) and the 10-year probability of hip fracture
[16,17]. Probability is calculated from age, sex, BMI and
dichotomized risk factors comprising prior fragility fracture,
parental history of hip fracture, current tobacco smoking, ever
Table 1 Comparison between the RA patients and control according to FRAX index (major osteoporotic fractures and hip fracture).
Percentage median (min.–max) RA patients (n= 25) Control (n= 20) Z p
10 year probability of:
Major osteoporotic fractures 4 (1.4–10) 1.85 (0.9–2.7) 4.73 <0.001
Hip fracture 0.1 (0–2.1) 0.04 (0–0.3) 3.86 <0.001
RA: Rheumatoid arthritis, FRAX: Fracture Risk Assessment Tool. Bold values are statistically signiﬁcant at p 6 0.05.
Table 2 Bone mineral density measurements in RA patients and control.
BMD (g/cm2) Mean ± SD RA patients (n= 25) Control (n= 20) t p
Femur neck 1.0 ± 0.1 1.1 ± 0.14 2.8 0.008
Wrist 0.64 ± 0.1 0.7 ± 0.07 2.05 0.046
L1–L4 1.07 ± 0.2 1.2 ± 0.12 2.98 0.005
RA: Rheumatoid arthritis, BMD: bone mineral density, L1–L4: lumbar vertebrae 1–4. Bold values are statistically signiﬁcant at p 6 0.05.
Table 3 Comparison between the RA patients and control
according to Z-score interpretation.






Normal for age 16 (64) 19 (95) 6.18 0.03
Below the expected range for
age
9 (36) 1 (5)
RA: Rheumatoid arthritis. Bold values are statistically signiﬁcant
at p 6 0.05.
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other causes of secondary osteoporosis and high alcohol
consumption.
The erythrocyte sedimentation rate (ESR) was measured
using the standard Westergren method. The C-reactive protein
(CRP) was assessed by the nephelometer assay, and Anti–
citrullinated protein antibody (ACPA) was measured for all
patients. Serum IL-17 levels were assessed using enzyme-
linked immunosorbent assay (ELISA) technique for both
patients and control [Human IL-17 Platinum ELISA,
BMS2017, eBioscience, USA].
Statistical analysis: was done using the IBM SPSS software
package version 20.0. Qualitative data were described using
number and percent. Quantitative data were described using
mean and standard deviation. Comparison between categori-
cal variables was tested using the Chi-square test. The distribu-
tions of quantitative variables were tested for normality using
Kolmogorov–Smirnov test, Shapiro–Wilk test and D’Agstino
test, also Histogram and QQ plot were used for vision test.
For normally distributed data, comparison between two inde-
pendent populations was done using independent t-test, corre-
lations between two quantitative variables were assessed using
the Pearson coefﬁcient. Abnormally distributed data were
assessed using Mann–Whitney test, and correlations between
two quantitative variables were assessed using Spearman coef-
ﬁcient. Signiﬁcance test results are quoted as two-tailed prob-
abilities. Signiﬁcance of the obtained results was judged at the
5% level.3. Results
The mean age of RA patients in the study was 38.8 ± 7.6 years
and of the control 38.7 ± 7.2 years (p= 0.95). The mean
duration of the disease was (7.04 ± 5.47) years ranging from
(1 to 20) years.
According to the DAS-28, 15 (60%) patients showed severe
activity, 9 (36%) showed moderate activity, but only one (4%)
showed mild disease activity score. Regarding the HAQ-DI in
RA patients, 15 (60%) patients experienced a mild to moderate
disability, 5 (20%) showed moderate to severe disability and 5
(20%) showed severe to very severe disability in their activity
of daily living.
Fracture Risk Assessment Tool (FRAX) showed a 10 year
probability of major osteoporotic fractures in the patients
ranging from 1.4 to 10%, with a median of 4%, while in the
control group it ranged between 0.9 and 2.7%, with a median
of 1.85% (p< 0.001) (Table 1). The range of 10 year probabil-
ity of hip fracture in the patients ranged between 0 and 2%,
with a median of 0.1%, while in the control group it ranged
between 0 and 0.3%, with a median of 0.035% (p< 0.001)
(Table 1).
The means of BMD in RA patients in femur neck, wrist and
lumbar vertebrae (L1-L4) were 1.0 ± 0.1, 0.64 ± 0.08,
1.07 ± 0.18 (g/cm2) respectively while the means of the control
were 1.11 ± 0.14, 0.68 ± 0.07, 1.21 ± 0.12 (g/cm2) in the
three measured sites. The BMD was signiﬁcantly lower in
patients compared to control p= 0.008, p= 0.046 and
p= 0.005 respectively (Table 2). A Z score of 2.0 or lower
was considered below the expected range for age. Z-score in
16 (64%) patients was normal for age compared to 19 (95%)
for control. While 9 (36%) patients were below the expected
range for age compared to 1(5%) for control (p= 0.027)
(Table 3).
The range of 1st hour ESR in the study group ranged
between 11.0 and 120 mm/h, with a mean level of 47.5
6 ± 29.51 mm/h. The CRP in the patient group ranged between
1.8 and 52 mg/l, with a mean level of 16.37 ± 14. 36 mg/l. The
range of ACPA in the patients group ranged between 11.4 and
525 U/ml, with a mean level of 105.34 ± 120.92. 80% of the
studied patients were ACPA positive.
Figure 1 Comparison between the RA patients and the control
according to serum IL-17 levels (pg/ml).
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patients was 5.99 ± 1.22 pg/ml, while in the control was
3.73 ± 2.15 pg/ml and the difference was statistically signiﬁ-
cant (p< 0.001) (Fig. 1).
Serum IL-17 levels showed a signiﬁcant correlation with the
FRAX index (10 year probability of major osteoporotic frac-
tures and hip fracture) in RA patients (p= 0.005 and
p= 0.013 respectively) (Figs. 2). The correlation was insignif-
icant in the control for both major osteoporotic and hip frac-
tures (p= 0.24 and p= 0.18 respectively).
Z-score interpretation showed a signiﬁcant correlation with
FRAX index (10 year probability of major osteoporotic frac-
tures and hip fracture) in RA patients (p= 0.002 and 0.03Figure 2 Correlation between serum IL-17 levels with FRAX index (
FRAX index (10 year probability of hip fracture) in RA patients (Rigrespectively) (Figs. 3). Regarding the control group, the corre-
lations were insigniﬁcant.
4. Discussion
The choice of premenopausal state was selected to exclude
effect of menopause on the occurrence of osteoporosis. In a
study on Egyptian RA patients, impaired bone formation
and uncoupling of bone turnover were evident in post-
menopausal cases with a higher risk of fracture hip [18].
DAS-28 in the current study represented all grades of disease
activity among the studied RA patients and also reﬂected
how much our patients had severely active RA. Regarding
the HAQ-DI, it covered all grades of functional disability
among the studied RA patients. The current results showed
that RA patients had signiﬁcantly higher FRAX index scores
than healthy subjects. Gonzalez-Lopez et al. [19], and Lee
et al. [20] had reported similar results but on Mexican and
Korean population respectively.
The current results showed that RA patients had signiﬁ-
cantly higher IL-17 serum level than healthy subjects. Rosu
et al. [11] reported that serum IL-17 was high in RA patients
and this supports the hypothesis that IL-17 family cytokines
are involved in the pathogenesis of RA as seen in previous
reports [9,12,21,22]. The current results showed that RA
patients had signiﬁcantly lower Z-scores mean values in all
measured sites (femoral neck, wrist and lumbar vertebrae
L1–L4) compared to healthy subjects. This ﬁnding runs in
accordance with previous published studies [6,23,24].
The current study showed no correlation between serum
levels of IL-17 and the disease activity. Failure to demonstrate
an association with DAS-28 is not to downplay the importance
of IL-17 in RA disease activity but it appears that not all our
patients were in the same activity state at time of sample with-
drawal. Moreover, the studied patients were established RA,
previously treated with a wide variety of DMARDs regimens,
which could inﬂuence both IL-17 behavior and the correlation
with the activity markers and the disease duration. Similarly,
in another study on Egyptian RA patients, IL-17 was signiﬁ-
cantly increased but did not correlate with any of the clinical
ﬁndings, laboratory and radiographic scores [25]. On the con-
trary, serum IL-17 was signiﬁcantly increased in RA patients
and signiﬁcantly correlated with DAS-28 and bone erosions10 year probability of major osteoporotic fracture) (Left) and with
ht).
Figure 3 Correlation between Z-score interpretation with FRAX index (10 year probability of major osteoporotic fracture) (Left) and
with FRAX index (10 year probability of hip fracture) in RA patients (Right).
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matory and destructive pattern characteristic of the disease
[26]. This discrepancy could be also attributed to the small
sample sizes as well as the different regions in Egypt from
which the patients were enrolled for each study.
As regards the relation between serum levels of IL-17 and
HAQ-DI, no signiﬁcant relationship between both parameters
could be detected. This result agreed with Yue et al. [27] who
found no correlation between serum levels of IL-17 and HAQ.
These results could be explained by that the HAQ-DI is
a subjective questionnaire which differs from one patient to
another according to assistance received from their relatives,
socioeconomic class of the patients, different levels of disease
activity or it may be attributed to the small sample size. In con-
tradiction to the previous results, Genovese et al. [28] reported
a strong relationship between serum IL-17 levels and HAQ-DI.
The current study showed a signiﬁcant correlation between
serum IL-17 levels and the FRAX index (both major osteo-
porotic and hip fractures). Also, IL-17 signiﬁcantly correlated
with the Z-score, where the serum IL-17 level was higher in
patients with Z-score below the expected range for age. This
result could be explained by the ﬁndings of Chabaud et al.
[9] who reported that high serum IL-17 levels were linked to
progressive destruction of cartilage and bone in RA patients.
Also, Lubberts et al. [29] clariﬁed that IL-17 is a crucial cyto-
kine in osteoclastogenesis and bone resorption. The Z score
interpretation as expressed by ISCD was found to be strongly
correlated with FRAX index. This might explain that our pre-
menopausal RA patients were found to have high z-score
interpretation (below the expected range for age) and high
serum levels of IL-17 and also a high FRAX index which in
turn explains the role of IL-17 in the occurrence of OP and
increases the risk of fractures even in premenopausal females.
Finding these results despite our selection of premenopausal
patients might be referred to their bad dietary habits which
are deﬁcient in calcium, corticosteroid intake, bad sleeping
habits which hinder their exposure to useful sunlight as being
the natural source of vitamin D, in addition to the chronic
inﬂammatory state. In another study on Egyptian RA patients,
vitamin D levels were signiﬁcantly lower than those in the
control [30].In rheumatoid arthritis (RA) patients, the risk of both
vertebral and non-vertebral fractures is roughly doubled,
which is for an important part caused by inﬂammation-
mediated ampliﬁcation of bone loss and by immobilization
[31]. Down regulation of IL-17 and IL-17-triggering cytokine
production was found to alleviate RA which highly supports
its role in the disease pathogenesis [32]. It is recommended that
future studies are conducted on larger sample sizes longitudi-
nally to verify our results.
In conclusion, the premenopausal rheumatoid arthritis
patients showed a high fracture probability. Interleukin-17





[1] Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau
K, et al. Risk of osteoporotic fracture in a large population-based
cohort of patients with rheumatoid arthritis. Arthritis Res Ther
2010;12(4):R154.
[2] Forsblad D’Elia H, Larsen A, Waltbrand E, Kvist G, Mellstrom
D, Saxne T. Radiographic joint destruction in postmenopausal
rheumatoid arthritis is strongly associated with generalised
osteoporosis. Ann Rheum Dis 2003;62(7):617–23.
[3] Perez-Lopez FR, Chedraui P, Cuadros-Lopez JL. Bone mass gain
during puberty and adolescence: deconstructing gender charac-
teristics. Curr Med Chem 2010;17(5):453–66.
[4] Shibuya K, Hagino H, Morio Y, Teshima R. Cross-sectional and
longitudinal study of osteoporosis in patients with rheumatoid
arthritis. Clin Rheumatol 2002;21(2):150–8.
[5] Jong Z, Munneke M, Lems WF, Zwinderman AH, Kroon HM,
Pauwels EK, et al. Slowing of bone loss in patients with
rheumatoid arthritis by long-term high-intensity exercise: results
of a randomized, controlled trial. Arthritis Rheum
2004;50(4):1066–76.
[6] Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux
C. Prevalence of vertebral fractures in patients with rheumatoid
arthritis: revisiting the role of glucocorticoids. Osteoporos Int
2012;23(2):581–7.
90 H.K. Korayem et al.[7] National Institute for Health and Clinical Excellence (NICE).
Osteoporosis: assessing the risk of fragility fracture. UK: NICE:
NICE Clinical Guideline 146; 2012.
[8] Borgstro¨m F, Stro¨m O, Coelho J, Johansson H, Oden A,
McCloskey EV, et al. The cost-effectiveness of risedronate in
the UK for the management of osteoporosis using the FRAX.
Osteoporos Int 2010;21(3):495–505.
[9] Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P.
IL-17 derived from juxta-articular bone and synovium contributes
to joint degradation in rheumatoid arthritis. Arthritis Res
2001;3(3):168–77.
[10] Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic
inﬂammation. Nat Rev Drug Discov 2012;11:763–76.
[11] Rosu A, Margaritescu C, Stepan A, Musetescu A, Ene M. IL-17
patterns in synovium, serum and synovial ﬂuid from treatment-
naive, early rheumatoid arthritis patients. Rom J Morphol
Embryol 2012;53(1):73–80.
[12] Volin MV, Shahrara S. Role of TH-17 cells in rheumatic and
other autoimmune diseases. Rheumatology (Sunnyvale) 2011;
1(104) (pii: 2169).
[13] Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham
3rd CO, et al. 2010 Rheumatoid arthritis classiﬁcation criteria:
an American College of Rheumatology/European League
Against Rheumatism collaborative initiative. Arthritis Rheum
2010;62(9):2569–81.
[14] Prevoo MLL, Hof van’t MA, Kuper HH, Leeuwen van MA,
Putte van de LBA, Riel van PLCM. Modiﬁed disease activity
scores that include twenty-eight-joint counts: development
and validation in a prospective longitudinal study of patients
with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
[15] Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis.
Arthritis Rheum 2000;43:2751–61.
[16] Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N,
et al. Interpretation and use of FRAX in clinical practice.
Osteoporos Int 2011;22(9):2395–411.
[17] Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J,
et al. The use of clinical risk factors enhances the performance of
BMD in the prediction of hip and osteoporotic fractures in men
and women. Osteoporos Int 2007;18:1033–46.
[18] Gheita T, Fawzy S, Rizk A, Hussein H. Impaired bone
formation and osteoporosis in postmenopausal elderly onset
rheumatoid arthritis patients. Egypt Rheumatol 2011;33(3):
155–62.
[19] Gonzalez-Lopez L, Gamez-Nava JI, Vega-Lopez A, Rodriguez-
Jimenez NA, Gonzalez-Montoya N, Aguilar-Chavez E, et al.
Performance of risk indices for identifying low bone mineral
density and osteoporosis in Mexican Mestizo women with
rheumatoid arthritis. J Rheumatol 2012;39(2):247–53.
[20] Lee JH, Suh YS, Koh JH, Jung S-M, Lee JJ, Kwok SK, et al. The
risk of osteoporotic fractures according to the frax model inKorean patients with rheumatoid arthritis. J Korean Med Sci
2014;29(8):1082.
[21] Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL.
Increasing levels of circulating Th17 cells and interleukin-17 in
rheumatoid arthritis patients with an inadequate response to anti-
TNF-a therapy. Arthritis Res Ther 2011;13(4):R126.
[22] Liu Y, Ho RC, Mak A. The role of interleukin (IL)-17 in anxiety
and depression of patients with rheumatoid arthritis. Int J Rheum
Dis 2012;15(2):183–7.
[23] Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone
mineral density and frequency of osteoporosis in female patients
with rheumatoid arthritis: results from 394 patients in the Oslo
County Rheumatoid Arthritis register. Arthritis Rheum
2000;43(3):522–30.
[24] Heidari B, Heidari P. Bone mineral density loss in post-
menopausal onset rheumatoid arthritis is not greater than
premenopausal onset disease. Caspian J Intern Med
2014;5(4):213–8.
[25] Al-Zifzaf DS, El-Bakry SA, Mamdouh R, Shawarby LA, Abdel-
Ghaffar AY, Amer HA, et al. FoxP3+T regulatory cells in
Rheumatoid arthritis and the imbalance of the Treg/TH17
cytokine axis. Egypt Rheumatol 2015;37(1):7–15.
[26] AlSaadany HM, Hussein MS, Gaber RA, Zaytoun HA. Th-17
cells and serum IL-17 in rheumatoid arthritis patients: correlation
with disease activity and severity. Egypt Rheumatol 2015 (in
Press, corrected proof, available online 3 March 2015).
[27] Yue C, You X, Zhao L, Wang H, Tang F, Zhang F, et al. The
effects of adalimumab and methotrexate treatment on peripheral
Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis
patients. Rheumatol Int 2010;30(12):1553–7.
[28] Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini
IM, Ryan P. LY2439821, a humanized anti-interleukin-17 mon-
oclonal antibody, in the treatment of patients with rheumatoid
arthritis: a phase I randomized, double-blind, placebo-controlled,
proof-of-concept study. Arthritis Rheum 2010;62(4):929–39.
[29] Lubberts E, Koenders MI, van den Berg WB. The role of T cell
interleukin-17 in conducting destructive arthritis: lessons from
animal models. Arthritis Res Ther 2005;7:29–37.
[30] Gheita TA, Sayed S, Gheita HA, Kenawy SA. Vitamin D status in
rheumatoid arthritis patients: relation to clinical manifestations,
disease activity, quality of life and ﬁbromyalgia syndrome. Int J
Rheum Dis 2014 Oct 7. http://dx.doi.org/10.1111/1756-
185X.12426 (Epub ahead of print).
[31] Hoes JN, Bultink IE, Lems WF. Management of osteoporosis in
rheumatoid arthritis patients. Expert Opin Pharmacother
2015;16(4):559–71.
[32] Ye L, Jiang B, Deng J, Du J, Xiong W, Guan Y, et al. IL-37
alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-
triggering cytokine production and limiting Th17 cell prolifera-
tion. J Immunol 2015;194(11):5110–9.
